Pharmaxis is a leader in mechanism-based inhibitors of amine oxidases. It has a proven ability to deliver Phase 2 trial ready compounds and an exciting pipeline of drug candidates for valuable targets. Its management team has the long standing expertise in the preclinical, early and late phase clinical trials required to secure successful drug development, as well as the strong industry relationships to deliver global transactions with major pharmaceutical partners.

Pharmaxis' research efforts are focused on discovering new drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, fibrosis of the liver and kidney, and cancer from the Company's world leading, proprietary amine oxidase inhibitor chemistry platform.

The Company’s strategy is to develop drugs to phase 1 or phase 2, depending upon the targeted disease and then seek to licence drugs to a large pharmaceutical company.


The first products from the Company’s amine oxidase platform have been inhibitors of the enzymes Semicarbazide-Sensitive Amine Oxidase (SSAO) and Lysyl Oxidase-Like type 2 (LOXL2). Both of these enzymes are involved in the inflammatory and fibrotic progression of numerous serious chronic diseases.

In May 2015 Pharmaxis sold its anti-inflammatory drug candidate PXS4728A, the first drug developed from the amine oxidase platform, to leading global pharmaceutical company Boehringer Ingelheim. The deal is one of the largest in Australian biotech history, included significant initial and future payments, and is firm recognition of the Company’s credentials in drug discovery.

In May 2017, Boehringer confirmed it would pursue a second indication for PXS-4728 in a separate phase 2 study, also commencing in 2017. Pharmaxis will receive
a milestone payment of €10m at the commencement of the trial in the second indication.

Other amine oxidase drug development programs currently being investigated by Pharmaxis include:

  • Selective LOXL2 inhibitor for pulmonary fibrosis
  • Selective LOXL2 inhibitor for NASH, liver and kidney fibrosis
  • Mixed LOXL/LOXL2 inhibitor: cancer; severe liver and kidney fibrosis (and tissue scarring)
  • SSAO/MAO-B inhibitor for neuro inflammation
  • SSAO/MPO inhibitor for lung inflammation, asthma, COPD

In August 2015 Pharmaxis announced a research collaboration with Synairgen plc to develop a LOXL2 inhibitor for pulmonary fibrosis. Pharmaxis expects to enter other collaborations to accelerate some of these programs while retaining others to develop independently. The possible application of LOX / LOXL2 inhibitors for the treatment of cancer and tissue scarring will be explored in collaboration with leading academic centres to get a better understanding of their potential.

The Pharmaxis product pipeline also includes: